Cologne

• A clinical study of V940 and pembrolizumab in people with melanoma (V940-012) Recruiting
  2024-519605-36-00 4 2025-08-08 Melanoma
• A study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of GSK4771261 in healthy participants and participants w … Recruiting
  2024-516095-15-00 1 2025-08-05 Kidney Disease
• A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia Recruiting
  2024-520154-38-00 5 2025-07-29 Acute Myeloid Luekemia
• Phase I open-label, multi-center study to evaluate the safety, tolerability, dosimetry, and preliminary activity of [177Lu]Lu-NNS309 in pati … Recruiting
  2023-510356-23-00 1 2025-07-18 Locally advanced or metastatic unresectable colorectal cancer (CRC)
• Fecal Microbiota Transfer in Liver Cancer to Overcome Resistance to Atezolizumab/Bevacizumab – A randomized, placebo-controlled, double-blin … Recruiting
  2023-506887-15-00 4 2025-07-14 Hepatocellular carcinoma
• A Study to Assess safety and Effectiveness of the Inavolisib Plus a CDK4/6 Inhibitor and Letrozole Versus Placebo Plus a CDK4/6 Inhibitor an … Recruiting
  2024-516162-11-00 5 2025-07-14 Endocrine-Sensitive phosphatidylinositol 3-kinase (PIK3CA)-Mutated, Ho
• A clinical study of patritumab deruxtecan (HER3-DXd) in children with cancer (MK-9999-01C) Recruiting
  2024-518771-66-00 9 2025-07-01 Hepatoblastoma, Rhabdomyosarcoma
• A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD5492 in Adult Participants with Systemic Lupus Ery … Recruiting
  2024-519015-34-00 1 2025-06-30 Systemic Lupus Erythematosus
• A Phase III study to evaluate the efficacy of INM004 (Shiga antitoxin) in pediatric patients with Shiga toxin-producing Escherichia coli-ass … Recruiting
  2024-512412-22-00 5 2025-06-24 Hemolytic Uremic Syndrome
• A study to assess safety, cellular kinetics and exploratory efficacy of rapcabtagene autoleucel in rheumatoid arthritis and Sjogren’s diseas … Recruiting
  2024-514596-18-00 9 2025-06-20 Difficult to treat rheumatoid arthritis
• A phase 3 multicenter, randomised, prospective, open-label trial of fixed-duration (12 cycles) venetoclax/ obinutuzumab vs. fixed-duration ( … Recruiting
  2023-510294-34-00 5 2025-06-12 small lymphocytic lymphoma (SLL)
• Study of Adagrasib plus Pembrolizumab plus Chemotherapy vs. Placebo plus Pembrolizumab plus Chemotherapy in Participants with Previously Unt … Recruiting
  2024-515698-85-00 5 2025-06-12 Locally Advanced or Metastatic Non-small Cell Lung Cancer
• REscue of Nephrons with ALe.F02 (RENAL F02) Recruiting
  2022-502184-38-00 4 2025-06-06 Rapidly progressive glomerulonephritis
• Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Smal … Recruiting
  2024-512302-25-00 5 2025-06-06 Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
• A Phase I/II study of GSK5733584 in combination with anti-cancer therapies for advanced solid tumors Recruiting
  2024-517147-31-00 9 2025-05-23 Tumours, Gynecological
• A clinical study of zilovertamab vedotin with R-CHP treatment in people with diffuse large B-cell lymphoma (MK-2140-011) Recruiting
  2024-515526-89-00 4 2025-05-16 Diffuse Large B-Cell Lymphoma (DLBCL)
• A study of N-Acetyl-L-Leucine on Ataxia-Telangiectasia Recruiting
  2024-517706-29-00 5 2025-05-13 Ataxia Telangiectasia
• A clinical trial to evaluate the safety and the efficacy of NEXAGON ® (Lufepirsen Ophthalmic Gel) in subjects with Persistent Corneal Epithe … Recruiting
  2023-507030-24-00 4 2025-04-30 Persistent Corneal Epithelial Defects
• Phase 3 study of belantamab mafodotin, lenalidomide, and dexamethasone (BRd) versus daratumumab, lenalidomide, and dexamethasone (DRd) in pa … Recruiting
  2024-516030-35-00 5 2025-04-30 Multiple myeloma
• Study of Intravenous Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor to Assess Adverse Events and Change in … Recruiting
  2024-514465-18-00 9 2025-04-23 Advanced or Metastatic Non-Squamous NSCLC
• SURVIVE HERoes – A randomized Secondary Adjuvant Treatment Intervention study comparing Trastuzumab-Deruxtecan to SOC therapy in eBC Patient … Recruiting
  2024-516173-76-01 5 2025-04-22 HER2-positive or HER2-low (incl. ultra-low) early breast cancer
• A phase II study assessing safety and efficacy of REPotrectinib in ROS1-positive non-small cell lung cancer patients with active brain mEtas … Recruiting
  2023-508112-35-00 4 2025-04-15 ROS1-positive non-small cell lung cancer (NSCLC) with active brain met
• A first-in-human clinical study to assess safety and tolerability of genetically modified T-cells in ROR1 positive tumors Recruiting
  2024-512019-36-00 1 2025-04-09 Adrenocortical carcinoma
• A Study to Understand the Optimization of the Cytokine Release Syndrome Profile for Glofitamab along with Gemcitabine Plus Oxaliplatin in Pa … Recruiting
  2024-516791-15-00 4 2025-04-08 Relapsed/Refractory Aggressive B-Cell Non-Hodgkin’s Lymphoma (NHL)

Showing 145–168 of 577 trials